Clinical trial
Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS)…
NCT00256126 · Merck KGaA, Darmstadt, Germany, Industry · Completed
Key facts
| NCT number | NCT00256126 |
|---|---|
| Title | Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN® |
| Official title | A Phase IV Open-label Study of Predictive Markers in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children Treated With SAIZEN® |
| Lead sponsor | Merck KGaA, Darmstadt, Germany, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Growth Hormone Deficiency, Turner Syndrome |
| Intervention type | Drug |
| Interventions | Saizen |
| Enrollment | 318 |
| Start date | May 31, 2005 |
| Primary completion | Sep 30, 2007 |
| Completion | Sep 30, 2007 |
| First posted | Nov 21, 2005 |
| Last update posted | Jun 26, 2018 |
| Countries | Argentina, Australia, Austria, Canada, France, Germany, Italy, Norway, Russia, Singapore, Spain, Sweden and 1 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: